SEC Tracker
Get the app

Aligos Therapeutics ALGS

Aligos Therapeutics Q3 FY23: revenue $1.1M; diluted EPS −$10.25

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Aligos Therapeutics reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$1.1MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$18.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$10.25No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported −$0.4110-Q income statement, on EDGAR
  4. Cash and cash equivalents$70.4MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  5. Cash from operations−$20.3MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Aligos Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. CEL-SCI CVM public float $19M, Mar 31, 2025, over 18 months old
  2. Relmada Therapeutics RLMD public float $19M, Jun 30, 2025
  3. Fibrogen FGEN public float $21M, Jun 30, 2025
  4. Armata Pharmaceuticals ARMP public float $21M, Jun 30, 2025
  5. Imunon IMNN public float $21M, Jun 30, 2025